These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).
Big Market Research “Global Crohns Disease Drug Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast. Visit for more info @ http://www.bigmarketresearch.com/global-crohns-disease-drug-industry-2015-deep-research-report-market The Global Crohns Disease drug Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.
Global crohn's disease treatment market size is expected to reach $16.32 Bn by 2028 at a rate of 6.7%, segmented as by drug type, antibiotics, amino salicylates, corticosteroids, immunomodulators, other drug types
The autoimmune disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 7.60% in the above-mentioned forecast period. Increasing awareness regarding healthcare sector drives the autoimmune disease treatment market. https://www.databridgemarketresearch.com/reports/global-autoimmune-disease-treatment-market
The Crohn’s & Colitis Foundation of America (CCFA) stated that over 1 Million Americans were diagnosed with Crohn’s & ulcerative colitis disorders, with most of them aged above 30. Growing occurrence of Crohn’s disease has triggered a robust demand for its therapeutics. A survey conducted by the US Center for Disease Control (CDC) has revealed that the incidence rate of Crohn’s disease in the country is 3.1 to 14.6 new cases per 100,000 population annually.
Inflammation is an action of the body’s immunity system to recover the injured tissues. However, inflammatory diseases are the diseases wherein this action of the immunity system gets compromised. Thus, inflammatory diseases in turn could lead to life threatening diseases as cancer and rheumatoid arthritis.
Inflammation is an action of the body’s immunity system to recover the injured tissues. However, inflammatory diseases are the diseases wherein this action of the immunity system gets compromised. Thus, inflammatory diseases in turn could lead to life threatening diseases as cancer and rheumatoid arthritis.
The disease is highly prevalent in developed countries, especially in individuals who smoke. According to a study conducted by Persistence Market Research (PMR), demand for anti-inflammatory drugs and biologics for treating Crohn’s disease will gain traction in the near future. PMR forecasts that the global market for Crohn’s disease is set to reach US$ 4,474.8 Million by 2024-end, growing at a CAGR of 3% during the assessment period.
The Global Crohn’s Disease Drug Industry report gives a comprehensive account of the Global Crohn’s Disease Drug market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report. Furthermore, this report features tables and figures that render a clear perspective of the Crohn’s Disease Drug market. Get Complete Report with TOC : http://www.qyresearchgroup.com/market-analysis/global-crohns-disease-drug-industry-2015-market-research.html
The China Crohn’s Disease Drug Industry report gives a comprehensive account of the China Crohn’s Disease Drug market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report. Furthermore, this report features tables and figures that render a clear perspective of the Crohn’s Disease Drug market. Get Complete Report with TOC : http://www.qyresearchgroup.com/market-analysis/china-crohns-disease-drug-industry-2015-market-research.html
BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecule and chiral compounds.
Global inflammatory bowel disease treatment market size is expected to reach $36.63 Bn by 2028 at a rate of 9.4%, segmented as by drug class, aminosalicylates, corticosteroids, tnf inhibitors, il inhibitors, anti-integrin, jak inhibitors
Global gastroesophageal reflux disease therapeutics market size is expected to reach $7.33 Bn by 2028 at a rate of 5.1%, segmented as by type, branded, generic
Bharat Book presents the report on “Migraine - Market Insights, Epidemiology and Market” (https://www.bharatbook.com/medical-devices-market-research-reports-814553/migraine-epidemiology2.html). It provides the therapeutics market revenue; average cost of therapy, treatment practice and Migraine forecasted market share for ten years to 2023 segmented by seven major markets.
Big Market Research “Global Inflammatory Bowel Disease Market” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast. Visit for more info @ http://www.bigmarketresearch.com/global-inflammatory-bowel-disease-2015-2019-market Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss.
OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. Analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019. Read more details at: http://www.bigmarketresearch.com/global-gastrointestinal-otc-drugs-2015-2019-market
The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors. Analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019. Read more details at: http://www.bigmarketresearch.com/global-inflammatory-bowel-disease-2015-2019-market
“Crohn's Disease - Pipeline Review, H2 2014”, provides an overview of the Crohn's Diseases therapeutic pipeline. For more details : http://goo.gl/1kdcXk
TBRC global inflammatory bowel disease treatment market report includes aminosalicylates, corticosteroids, tnf inhibitors, il inhibitors, anti-integrin, jak inhibitors https://bit.ly/3p5WyWH
Smart pills have emerged as a revolutionary technological innovation, bridging the gap between digital technology and healthcare. Advent of these healthcare-cum-technological devices has enabled addressing soaring demand for better monitoring and diagnostics.
Bharat Book Bureau provides the report on “Global Human Microbiome-based Drugs Market”, (https://www.bharatbook.com/diagnostics-market-research-reports-644540/human-microbiome-based-drugs-diagnostics-global.html) The report provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Data Bridge Market Research analyses that the ribonucleic acid (RNA) interference market is expected to grow at a CAGR of 19.35% during the forecast period of 2022 to 2029. The “therapeutics” segment accounts for the largest application segment in the ribonucleic acid (RNA) interference market within the forecasted period.
The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%.
Autoimmune diseases develop when body’s immune system recognizes the healthy body cells as foreign cells, and when immune system produces auto-antibodies that attack and destroy healthy tissues in the body rather than infectious agents. The disease is the hyperactive immune response against the substances and tissues normally present in the body and these are generally caused by genetic, infectious or environmental factors. It may lead to abnormal organ growth and changes in the functions of the organs.
Global Drug Delivery Devices Market is segmented based on product type, end-user, distribution channel, and geography. https://www.bharatbook.com/healthcare-market-research-reports-920944/global-drug-delivery-trends.html
Autoimmune diseases develop when body’s immune system recognizes the healthy body cells as foreign cells, and when immune system produces auto-antibodies that attack and destroy healthy tissues in the body rather than infectious agents. The disease is the hyperactive immune response against the substances and tissues normally present in the body and these are generally caused by genetic, infectious or environmental factors. It may lead to abnormal organ growth and changes in the functions of the organs.
Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024
Global autoimmune disease treatment market is set to witness a substantial CAGR of 7.60% in the forecasted period of 2019-2026. This rise in the market can be attributed due to enhancement in autoimmune diagnosis and technology advancement in the industry.
Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Moderate Pain. Browse full report @ http://bit.ly/19yaEYf
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Ovarian Cancer. Browse full report @ http://bit.ly/1Ls5dLa
Global tumor necrosis factor (TNF) inhibitor drugs market is expected to rise to an estimated value of USD 182.27 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026. Rising cases of Crohn’s disease and increasing demand for effective treatment are the major factor for the growth of this market.
Global tumor necrosis factor (TNF) inhibitor drugs market is expected to rise to an estimated value of USD 182.27 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026. Rising cases of Crohn’s disease and increasing demand for effective treatment are the major factor for the growth of this market.
Global autoimmune disease treatment market is set to witness a substantial CAGR of 7.60% in the forecasted period of 2019-2026. This rise in the market can be attributed due to enhancement in autoimmune diagnosis and technology advancement in the industry.
The global referral management market is estimated to grow at a CAGR of 22.1% from 2014 to 2019 to reach $2,686.3 million by 2019 from $988 million in 2014. The healthcare industry is undergoing a fundamental transformation globally as it shifts from a volume-based business to a value-based business. Growing demands from consumers for improved healthcare quality and greater value are forcing healthcare providers and payers to deliver optimized outcomes. See Full Report : http://bit.ly/1FKZ0GB
Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment. Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more.
Nicotine USP, or United States Pharmacopeia-grade nicotine, is a high-purity form of nicotine that is used in a variety of pharmaceutical and industrial applications. The global nicotine USP market is expected to grow from USD 392.9 million in 2021 to USD 1,022.17 million by 2030, at a CAGR of 7.5% during the forecast period.
??????? * * Blues and purples not only add beautiful shades of tranquility and richness to your plate, they add health-enhancing flavonoids, phytochemicals, and ...
The global Human Microbiome Market is forecasted to be worth USD 1,689.5 Million by 2027, according to a current analysis by Emergen Research. The Human Microbiome market is anticipated to grow substantially owing to the rising awareness of human microbiome therapy. The market is also expected to boost by increasing favorable regulations on probiotics and prebiotics by regulatory bodies. Besides, the growing prevalence of chronic diseases is forecasted to further propel the market growth over the forecast timeframe.
... preoperative cytostatic treatment in patients with locally advanced solid tumors; ... used in the treatment of cancer interfere with the production ...
“Crohn's Disease - Pipeline Review, H2 2014”, provides an overview of the Crohn's Diseases therapeutic pipeline. For more details : http://goo.gl/1kdcXk
Adalimumab Market Size is estimated to reach $5.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.1% over the forecast period of 2022-2027.
The global mesalamine market size is estimated to grow from USD 169.5 million in 2020 and reach USD 211.6 million by 2027, at a CAGR of 3.4% over the forecast period, 2021-2027. Mesalamine, also known as Mesalazine, is a prescription drug containing 5-aminosalicylic acid that helps cure ulcerative colitis (UC) and other inflammatory bowel disorders. Mesalamine is known as the first-line agent for the treatment of active UC and preservation of clinical recovery. It has been reported as the active anti-inflammatory agent used since the 1940s to treat UC. Several different types of mesalamine medications can be distinguished based on their means of delaying mesalamine release until it reaches the colon.
Favourable reimbursement coverage in selected countries, technological advancements in capsule endoscopes and rise in incidences of colon cancer will likely to accelerate the growth of the smart pills market in the forecast period of 2020-2027. On the other hand, growing necessity of rapid drug development process will further boost various opportunities that will lead to the growth of the smart pills market in the above mentioned forecast period.